InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches fIVE Calculator. Initially, fIVE DB (from In Vitro Experiments DataBase) is an InSysBio project for in vitro experiments information collection and processing. fIVE DB is designed for QSP modelers and scientists who deal with in vitro/ex vivo data analysis to simplify their hard work and avoid potential errors. Information collected in the database enables them to save time typically spent for gathering and processing of literature and available data.
Now InSysBio presents public beta release of fIVE Calculator which is a web application designed to automatically calculate kinetic parameters from in vitro experiments for modeling of biosystems. The Calculator contains the input fields for the details of in vitro experiments, measurement units and uncertainties. Time- and dose-dependent datasets allows yielding kbase/kmax and Emax/EC50 correspondingly.
Graphical representation helps to visualize the input data and highlights the points picked up by the user for parameters estimation. Parameters are calculated automatically and then displayed in the results table.
Alexander Stepanov, the developer of the Calculator comments on it, “Here we present Shiny application to demonstrate the features of the framework built-in in fIVE DB as well as to provide a possibility to estimate parameters without fitting from available in vitro experiments”.
fIVE Calculator available at https://step-by-step.shinyapps.io/five-db-calculator/
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
← | October 2024 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
1.
04 Oct 2024 16:13
InSysBio to participate in SITC 2024
InSysBio announces its participation in SITC’s 39th Annual Meeting which is to be held from November 6-10, 2024, at George R. Brown Convention Center in Houston, TX, USA. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1032 and 3 posters in frames of the Meeting
|
5
|
6
| |
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
1.
16 Oct 2024 19:36
InSysBio to take part in "An Introduction to QSP" event
InSysBio announces its participation in An Introduction to QSP, A UK QSP Network hybrid (in person/online) event which is to be held 17-20hrs 24th October 2024. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will discuss the prediction of the first-in-human dose for T-cell engagers using mechanistic modelling
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|